CLINICAL STRATEGIES OF 5-FLUOROURACIL: A PROMOSING APPROACH FOR CARCINOMA THERAPY
PhD Research Scholar, Department of Chemistry, School of life Sciences, Jaipur National University (JNU), Rajasthan
Pradeep Kumar Swain
PhD Research Scholar, Department of Chemistry, School of life Sciences, Jaipur National University (JNU), Rajasthan
Shaik Kareemulla
PhD Research Scholar, Department of Chemistry, School of life Sciences, Jaipur National University (JNU), Rajasthan
Rama S. Lokhande
PhD Research Scholar, Department of Chemistry, School of life Sciences, Jaipur National University (JNU), Rajasthan
Zoheb Anjum
Bachelor of pharmacy, Jawaharlal Nehru Technological University (JNTU), Hyderabad, Telangana, India.
Mohd Abdul Raheem
Bachelor of pharmacy, Jawaharlal Nehru Technological University (JNTU), Hyderabad, Telangana, India.
Shaifiqur Rahman Khalid
Bachelor of pharmacy, Jawaharlal Nehru Technological University (JNTU), Hyderabad, Telangana, India.
5-Fluorouracil has been used for more than 40 years in the treatment of colorectal cancer. 5-Fluorouracilis given intravenously and has been used in a variety of different schedules to determine the optimum dose and mode of administration. Although 5-Fluorouracilin combination with other chemotherapeutic agents improves response rates, but in colorectal cancer 5-Fluorouracilhad the greatest impact. Strategies that have been explored to modulate the anticancer activity of 5-Fluorouracilinclude decreasing 5-Fluorouracildegradation, increasing 5-Fluorouracilactivation and increasing the TS binding activity of FdUMP. Understanding the mechanisms by which 5-Fluorouracilcauses cell death and by which tumors become resistant to 5-Fluorouracilis an essential step towards predicting or overcoming that resistance. Several studies have demonstrated that administration of anti-inflammatory agents decreases the toxicity of conventional chemotherapeutic agents. For example, combining celecoxib with docetaxel decreased hematologic toxicity in patients with refractory metastatic prostate cancer, even though it only slightly decreased the pain index for patients.
8 , 1 , 2018
1 - 7
Subscriber Login
